Precision medicine in AML: overcoming resistance

No abstract is available for this paper.

• Publication year

  2024

• Venue

  International journal of hematology

• Publication date

  2024-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12185-024-03827-8PMID 39085680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

  2023cited by this paper
• A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

  2023cited by this paper
• Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

  2023cited by this paper
• Mechanisms of BCL-2 family proteins in mitochondrial apoptosis

  2023cited by this paper
• Glue-based KRAS inhibitors make their debut cancer trial mark

  2023cited by this paper
• Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.

  2023cited by this paper
• Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

  2023cited by this paper
• Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2023cited by this paper
• The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

  2023cited by this paper
• Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse

  2023cited by this paper
• Perturbed autophagy intervenes systemic lupus erythematosus by active ingredients of traditional Chinese medicine

  2023cited by this paper
• FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

  2022cited by this paper
• Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

  2022cited by this paper
• A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

  2022cited by this paper
• Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

  2022cited by this paper
• Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

  2022cited by this paper
• A digital mask to safeguard patient privacy

  2022cited by this paper
• Recent advances of IDH1 mutant inhibitor in cancer therapy

  2022influential reference
• Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

  2022cited by this paper
• Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.

  2022cited by this paper
• Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

  2022cited by this paper
• A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

  2022cited by this paper
• Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

  2022cited by this paper
• Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

  2022cited by this paper
• Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

  2021cited by this paper
• Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

  2021cited by this paper
• Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

  2021cited by this paper
• Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

  2021cited by this paper
• Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

  2021cited by this paper
• Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

  2021cited by this paper
• Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

  2021cited by this paper
• Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

  2021cited by this paper
• 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

  2021influential reference
• Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

  2020cited by this paper
• Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

  2020cited by this paper
• Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients.

  2020cited by this paper
• Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

  2020cited by this paper
• Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis

  2020cited by this paper
• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

  2020influential reference
• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

  2020cited by this paper
• Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.

  2020cited by this paper
• Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

  2020cited by this paper
• Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

  2020cited by this paper
• Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies

  2019cited by this paper
• Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

  2019cited by this paper
• Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

  2019cited by this paper
• Targeting FLT3 mutations in AML: review of current knowledge and evidence

  2019cited by this paper
• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

  2019cited by this paper
• AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

  2018cited by this paper
• MCL-1 inhibition in cancer treatment

  2018cited by this paper
• Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

  2018cited by this paper
• Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

  2018cited by this paper
• Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

  2018cited by this paper
• Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

  2018cited by this paper
• Biological Role and Therapeutic Potential of IDH Mutations in Cancer.

  2018cited by this paper
• Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

  2018cited by this paper
• A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

  2018cited by this paper
• Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

  2018cited by this paper
• Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017cited by this paper
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  2017cited by this paper
• Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

  2017cited by this paper
• DNA sequencing at 40: past, present and future

  2017cited by this paper
• Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.

  2017cited by this paper
• Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

  2016cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Isocitrate dehydrogenase mutations in myeloid malignancies

  2016cited by this paper
• FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

  2016cited by this paper
• Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

  2015cited by this paper
• New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia

  2015cited by this paper
• Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

  2015cited by this paper
• Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)

  2015cited by this paper
• FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

  2015cited by this paper
• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

  2015cited by this paper
• Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

  2014cited by this paper
• Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

  2014cited by this paper
• Crenolanib is a selective type I pan-FLT3 inhibitor

  2014cited by this paper
• Identification of pre-leukemic hematopoietic stem cells in acute leukemia

  2014cited by this paper
• BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

  2014cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia

  2013cited by this paper
• Genentech: The Beginnings of Biotech

  2013cited by this paper
• Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

  2013cited by this paper
• An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

  2013cited by this paper
• IDH mutation impairs histone demethylation and results in a block to cell differentiation

  2012cited by this paper
• Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

  2012cited by this paper
• Cerebral Neoplasms in L-2 Hydroxyglutaric Aciduria: 3 New Cases and Meta-Analysis of Literature Data

  2012cited by this paper
• FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

  2011cited by this paper
• Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

  2011cited by this paper
• Genentech: The Beginnings of Biotech

  2011cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• Funding of US biomedical research, 2003-2008.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

  2009cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper

• De la biología molecular al tratamiento: medicina de precisión en leucemia mieloide aguda

  2026cites this paper
• Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer

  2025cites this paper
• Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias

  2025cites this paper
• Screening for Antileukemia Agents in FMS-like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia Cells.

  2025cites this paper
• Mortality and relapse dynamics in AML after three years of complete remission

  2025cites this paper
• Recent advances in cells, nanoparticles, and cell membrane coated nanoparticles for acute myeloid leukemia treatment

  2024cites this paper